ArticleNature communications2025
Flexible graphene-based neurotechnology for high-precision deep brain mapping and neuromodulation in Parkinsonian rats.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Full-Stack Architectures for Intelligent Brain-Computer Interfaces.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- An artefact-resilient wide bandwidth bidirectional graphene neural interface.Nature communications · 2026Article
- Technical considerations of functional MRI in deep brain stimulation: recent advances and future perspectives.NeuroImage · 2026Review
- Cognitive trajectories in Parkinson's disease patients, a review on the impact of subthalamic deep brain stimulation (STN-DBS) and emerging adaptive strategies.Translational psychiatry · 2026Review
- Atomically Precise Clusterzymes: A Programmable Optoelectronic Platform for Neuroscience.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Multi-Channel Neural Interface for Neural Recording and Neuromodulation.Small methods · 2026Review
- Recent advances of in situ and in vivo electrochemical analysis of brain chemistry at micro- and nanoscale.QRB discovery · 2026Review
- Long-Term Stable Neural Interfaces with Nanoporous Graphene Electrodes and Hybrid Polyimide-Aluminium Oxide Encapsulation.Small methods · 2025Article
- Multifunctional hydrogel sensors with dynamic covalent networks for machine learning-assisted Parkinson's disease diagnosis and encrypted human-computer interaction.Materials today. Bio · 2025Article
- Interplay Among Synaptic Glutamate Release and Excitotoxicity: Neuronal Damage and Graphene-Based Materials Related Protection.Life (Basel, Switzerland) · 2025Review
- Neural vs Neuromorphic Interfaces: Where Are We Standing?Chemical reviews · 2025Review
- State-of-the-art preclinical techniques to study the impact of spreading depolarizations in awake rodents.The journal of headache and pain · 2025Review
- Functional Nanomaterials for Advanced Bioelectrode Interfaces: Recent Advances in Disease Detection and Metabolic Monitoring.Sensors (Basel, Switzerland) · 2025Review
- Reliability and stability of Bioelectronic Medicine: a critical and pedagogical perspective.Bioelectronic medicine · 2025Review
- Epilepsy grand challenge 2025.Frontiers in neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deep brain stimulation (DBS) is a neuroelectronic therapy for the treatment of a broad range of neurological disorders, including Parkinson's disease. Current DBS technologies face important limitations, such as large electrode size, invasiveness, and lack of adaptive therapy based on biomarker monitoring. In this study, we investigate the potential benefits of using nanoporous reduced graphene oxide (rGO) technology in DBS, by implanting a flexible high-density array of rGO microelectrodes (25 µm diameter) in the subthalamic nucleus (STN) of healthy and hemi-parkinsonian rats. We demonstrate that these microelectrodes record action potentials with a high signal-to-noise ratio, allowing the precise localization of the STN and the tracking of multiunit-based Parkinsonian biomarkers. The bidirectional capability to deliver high-density focal stimulation and to record high-fidelity signals unlocks the visualization of local neuromodulation of the multiunit biomarker. These findings demonstrate the potential of bidirectional high-resolution neural interfaces to investigate closed-loop DBS in preclinical models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.